Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.57 |
| ▸ | CD74 | P04233 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | SCN4A | P35499 | 3/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29956087 | 0.98 | NOTUM (0.56) | NOTUMCD74MIFSCN4AMGLL | |
| Water SCHEMBL25434196 | 0.98 | NOTUM (0.56) | NOTUMCD74MIFSCN4AMGLL | |
| SCHEMBL17279815 | 0.81 | NOTUM (0.74) | NOTUMCD74MIFSCN4ACYP2E1 | |
| SCHEMBL2263770 | 0.78 | POLB (0.57) | NOTUMSCN4AMGLLCYP2E1CYP2A6 | |
| SCHEMBL30456423 | 0.77 | NOTUM (0.69) | NOTUMCD74MIFSCN4ACYP2E1 | |
| SCHEMBL25272432 | 0.77 | NOTUM (0.69) | NOTUMCD74MIFSCN4ACYP2E1 | |
| SCHEMBL28534927 | 0.76 | NOTUM (0.53) | NOTUMCD74MIFSCN4ACYP2E1 | |
| SCHEMBL12619984 | 0.74 | MGLL (0.86) | MGLLPLGF12F11KLKB1 | |
| SCHEMBL30712840 | 0.74 | MGLL (0.86) | MGLLPLGF12F11KLKB1 | |
| SCHEMBL31139484 | 0.74 | MGLL (0.86) | MGLLPLGF12F11KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-10-07 | — | — | US | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-05-16 | — | — | US | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2615918-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| WO-2013041457-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037298-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435047-B2 | c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | NOTUM 3625/4885CD74 3990/4885MIF 2292/4885 |
| US-20230303501-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | NOTUM 3625/4885CD74 3990/4885MIF 2292/4885 |
| US-11649218-B2 | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same | ABL1, ABL2, MUSK | NOTUM 3625/4885CD74 3990/4885MIF 2292/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | NOTUM 1118/4885CD74 3537/4885MIF 1477/4885 |
| US-20250340521-A1 | C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | ABL1, ABL2, MUSK | NOTUM 3625/4885CD74 3990/4885MIF 2292/4885 |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NOTUM 174/4885CD74 3768/4885MIF 1366/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | NOTUM 4069/4885CD74 993/4885MIF 2441/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NOTUM 228/4885CD74 3601/4885MIF 2276/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | NOTUM 160/4885CD74 4355/4885MIF 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.